Oncology  Conference update

ER+ advanced breast cancer: Highlights from EBCC-14 satellite symposium

Medical experts discuss current and upcoming treatment strategies to use after CDK4/6 inhibitors in patients with ER+/HER2- advanced breast cancer

Prof. Valentina Guarneri

Prof. Valentina Guarneri
Prof. Matteo Lambertini

Prof. Matteo Lambertini
Prof. Federico Rojo

Prof. Federico Rojo

Publication Date

Mar 2024

menu

In this conference update video, Prof. Valentina Guarneri, Prof. Matteo Lambertini, and Prof. Federico Rojo summarise the key points presented at the highly anticipated EBCC-14 Industry Satellite Symposium and review the current and future treatment landscape for ER+/HER2- advanced breast cancer, with a focus on the metastatic luminal subtype.

 

Topics of discussion include:

  • Overview of the ESMO metastatic breast cancer living guidelines
  • Impact of endocrine resistance and sensitivity
  • The benefit of biomarker-selected endocrine-based therapies in ER+/HER2- advanced breast cancer
  • ESR1 mutation: clinical significance and testing strategies

 

Clinical Takeaways

  • Biomarker-selected endocrine therapies show greater PFS benefits in specific patient subgroups
  • Elacestrant, the first oral SERD to obtain FDA & EMA approval, demonstrates optimal efficacy in ESR1-mutated ER+/HER2- mBC following CDK4/6i treatment
  • Capivasertib, FDA-approved based on the CAPItello-291 study for AKT-pathway altered population, awaits EMA approval as of March 2024
  • ESR1 mutation, holding both prognostic and predictive value, warrants testing upon ET recurrence or progression, using tissue or liquid biopsy

Educational Objectives

  • Conduct a thorough evaluation to determine the underlying causes of HR-positive, HER2-negative breast cancer progression (with a focus on the metastatic luminal subtype)
  • Know the role and be able to implement genomic testing appropriately
  • Implement optimisation of treatment selection, and make the appropriate sequencing decisions in the context of shared decision making

"Valentina Guarneri, MD, PhD, is Full Professor of Oncology at the University of Padua, Head of the Division of Oncology 2 at the Istituto Oncologico Veneto, and head of the Specialization School in medical Oncology at the University of Padova. She completed her fellowship in Oncology in 2003, and she obtained her PhD Degree in Clinical and Experimental Oncology in 2007. In 2005 she was appointed Assistant Professor of Oncology at the University of Modena and Reggio Emilia, where she also chaired the Breast Unit. In 2005, she also completed a 6-month-research experience at the Department of Breast Medical Oncology, UT. MD Anderson Cancer Center, Houston, Texas, where in 2009 she was Visiting Assistant Professor. In 2014 she was appointed Associate Professor of Oncology at the University of Padua.  Prof Guarneri’s research interest is mainly focused on clinical and translational research for breast cancer patients. She has published more than 200 papers in peer-reviewed journals."

Prof. Valentina Guarneri has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Advisory Role: Eisai, Eli Lilly, Exact Sciences, Gilead, Merck Serono, MSD, Novartis, Olema Oncology.

Speakers bureau: Amgen, Eli Lilly, GSK, Gilead, AstraZeneca, Novartis.

Expert testimony: Eli Lilly

Programme summary
Watch the video now
Share this programme
x-twitter
This educational programme is supported by an Independent Educational Grant from Menarini Stemline.
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from Menarini Stemline.
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
BREAST CANCER CONNECT

BREAST CANCER CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from Menarini Stemline Oncology, AstraZeneca and Thermo Fisher Scientific.

Meet the experts Independent IME approved

Other programmes of interest

conference-update Conference update
Oncology 
ER+ metastatic breast cancer: Highlights from the 13th APBCS Satellite Symposium

Medical experts discuss treatment strategies and sequencing after ET + CDK4/6i for ER+/HER2- metastatic breast cancer  

Experts
Prof. Shaheenah Dawood, Prof. Heather McArthur, Prof. Javier Cortés, Prof. Frédérique Penault-Llorca
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Feb 2025
COR2ED
This programme has been sponsored by Menarini Stemline and is intended for healthcare professionals only.
podcast Podcast
Hemostasis and bleeding disorders Oncology 
Σειρά podcast για τη διαχείριση της θρόμβωσης

Αναλύσεις από καταξιωμένους ειδικούς ιατρούς. Πλοηγηθείτε στις καρτέλες για να επιλέξετε ένα επεισόδιο podcast

Experts
Prof. Dimitrios Tsakiris, Prof. Michael Nagler, Dr Lars Asmis, Prof. Jerzy Windyga
  • download Downloadable
    Resources
  • clock 27 MIN
  • calendar Feb 2025
COR2ED Non-accredited Independent Medical Education
This educational programme is supported by an Independent Educational Grant from Viatris.
conference-update Conference update
Oncology 
ESMO Virtual Plenary: Final OS results from the phase III TROPION-Breast01 trial

How will the latest Dato-DXd data impact treatment strategies for HR+/HER2− mBC?

Experts
Prof. François-Clément Bidard, Dr Barbara Pistilli
  • clock 5 MIN
  • calendar Feb 2025
BREAST CANCER CONNECT
Educational programme supported by an Independent Educational Grant from AstraZeneca
podcast Podcast
Oncology Obstetrics and Gynecology 
Advanced or recurrent endometrial cancer: Molecular classification and treatment decisions

Understanding the role of molecular subtypes in guiding treatment selection

Experts
Prof. Xavier Matias-Guiu, Dr Jurjees Hasan
Endorsed by
Biomarker Collaborative ICAN international cancer advocacy network
  • download Downloadable
    Resources
  • clock 11 MIN
  • calendar Feb 2025
OBSTETRICS & GYNECOLOGY CONNECT  PRECISION ONCOLOGY CONNECT Non-accredited Independent Medical Education
This programme has been sponsored by Eisai Europe Limited ("Eisai"). Eisai has had no input on the educational content of, or speakers involved in this Video Podcast.
podcast Podcast
Hemostasis and bleeding disorders Oncology 
Postępowanie w przypadku zakrzepicy – seria podcastów

Uznani eksperci dzielą się swoimi spostrzeżeniami. Kliknij na odpowiednią zakładkę, aby wybrać odcinek podcastu.

Experts
Prof. Dimitrios Tsakiris, Prof. Michael Nagler, Dr Lars Asmis, Prof. Jerzy Windyga
  • download Downloadable
    Resources
  • clock 27 MIN
  • calendar Feb 2025
COR2ED Non-accredited Independent Medical Education
This educational programme is supported by an Independent Educational Grant from Viatris.
conference-update Conference update
Oncology 
Highlights from ASCO GI 2025

Expert insights on BRAF-mutated colorectal cancer

Experts
Dr Elena Élez
Endorsed by
DiCE BRAF Bombers ICAN international cancer advocacy network
Biomarker Collaborative
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Feb 2025
GI CONNECT PRECISION ONCOLOGY CONNECT GI NURSES CONNECT Non-accredited Independent Medical Education
Educational programme supported by an Independent Educational Grant from Pierre Fabre Laboratories. The programme is therefore independent, the content is not influenced by Pierre Fabre Laboratories and is under the sole responsibility of the experts. This content is intended for HCPs outside the UK and ROl only.
Explore all programmes